MILLENNIUM PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
Phase 1
Completed
- Conditions
- Relapsed/Refractory LymphomaAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2014-08-12
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02214147
A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction
Phase 2
Terminated
- Conditions
- Adenocarcinoma of the StomachGastroesophageal Junction Expressing Guanylyl Cyclase C
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT02202759
A Study of MLN0264 in Patients With Pancreatic Cancer
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02202785
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT02135445
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2014-04-25
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02122770
- Locations
- 🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
🇺🇸Siteman Cancer Center - South County, Saint Louis, Missouri, United States
A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects
Phase 1
Completed
- Conditions
- Prostate CancerEndometriosis
- Interventions
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02093390
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT02083185
A Phase I Study of MLN6907 in Patients With Metastatic Colorectal
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2017-01-05
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02056015
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
Phase 2
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2014-01-27
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 148
- Registration Number
- NCT02046070
A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT02045095
© Copyright 2025. All Rights Reserved by MedPath